GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Debt-to-Asset

XTL Biopharmaceuticals (XTAE:XTLB) Debt-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Debt-to-Asset?

XTL Biopharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₪0.00 Mil. XTL Biopharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₪0.00 Mil. XTL Biopharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ₪10.96 Mil. XTL Biopharmaceuticals's debt to asset for the quarter that ended in Mar. 2024 was 0.00.


XTL Biopharmaceuticals Debt-to-Asset Historical Data

The historical data trend for XTL Biopharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Debt-to-Asset Chart

XTL Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XTL Biopharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XTL Biopharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, XTL Biopharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Debt-to-Asset falls into.



XTL Biopharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

XTL Biopharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

XTL Biopharmaceuticals's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XTL Biopharmaceuticals  (XTAE:XTLB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


XTL Biopharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


XTL Biopharmaceuticals Business Description

Traded in Other Exchanges
Address
26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.